TickerTalks
Browse all tickers →
TickerTalks›$GILD
GIGILD

Gilead Sciences, Inc.

$GILD·$165B·Drug Manufacturers - General·Healthcare
$146.34+0.5%YTD+10.4%1Y+29.8%
Mentions · last 7 days
2026-08-22: 6 posts271+2%
Price updated 7h ago·X counts updated 9d ago
GIGILD
$GILDGilead Sciences, Inc.
$146.34+0.45%271 posts+2%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GILD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-29

The move is getting stronger, with heavier trading behind it.

Gilead's Bixlenvo HIV approval extends the franchise plus Trodelvy label expansion — quality biotech compounder pushing toward $150.

Gilead Sciences is one of the largest biotech companies globally — HIV franchise (Biktarvy, Descovy) as the anchor, plus a scaling oncology portfolio (Trodelvy, Yescarta CAR-T) and a hepatitis-C legacy franchise. The setup is a real-business compounder catching two catalysts at once.

  • The Bixlenvo FDA approval is the fresh catalyst: FDA approved Bixlenvo (bictegravir/lenacapavir) as the smallest once-daily HIV single-tablet regimen — a real product-lifecycle extension for the HIV franchise (Q2 HIV sales were +12% YoY to $5.7B), and the tape flagged above $145 targeting $150-160 on the news.
  • The oncology tape is also positive: expanded EU label for Trodelvy in first-line triple-negative breast cancer (TNBC) adds real incremental revenue, and the sell side models FY26 revenue at ~$30.4B with EPS turning positive in FY27 at ~$9.65 — the trailing 17x P/E is cheap for a business generating 38% operating margin and 20% ROIC.
  • The insider signal is loud: EVP Mercier sold ~$3.85M and multiple directors sold on August 20-26 after M-Exempt exercises — combined ~$7M+ of officer/director selling into strength suggests fair value is close to here in insider eyes, not that the story is broken.

The setup is a real-business quality biotech accelerating on two fresh drug approvals — the October 29 Q3 print is the referee, and the market needs continued HIV franchise growth plus updated Trodelvy TNBC launch color. A clean beat plus a lifted FY guide breaks the accelerating trajectory further up toward $160; another cluster of officer selling above $150 or a soft Trodelvy launch cools the tape from the 52-week range top.

Agrees with X sentimentThe bullish X read on the FDA approval of Bixlenvo as the smallest once-daily HIV STR, Q2 HIV sales +12% YoY to $5.7B, expanded EU Trodelvy first-line TNBC label, and the $150-160 target is factually consistent with the announcements. The ~$7M+ officer/director selling cluster on August 20-26 is the counter-tell the crowd doesn't yet price against.

What to watch: The October 29 Q3 earnings — need continued HIV franchise growth (Bixlenvo launch color), updated Trodelvy TNBC launch color, and a lifted FY guide. Another cluster of officer selling above $150 or a soft Trodelvy launch cools the tape from the 52-week range top; a clean beat plus a lifted FY guide breaks the accelerating trajectory further up toward $160.

On the calendar: 2026-10-29 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-31

Bullish tone as the FDA cleared Bixlenvo (bictegravir/lenacapavir) — a once-daily single-tablet HIV regimen for virologically-suppressed adults on complex multidrug regimens — on the PDUFA date. Posters frame it as extending the HIV moat against GSK/ViiV and cite Biktarvy's $3.77B Q2 print. Chartists note a $145 price-target hit with $150 as the next trendline test, and an EU expansion of Trodelvy in first-line metastatic TNBC adds a secondary tailwind.

Read the AI verdict + X sentiment for $GILD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells Biktarvy for HIV, Veklury for COVID, and Trodelvy for oncology; large-cap specialty pharma with antiviral and cancer drug focus.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $GILD.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $GILD

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+45.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
17.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
20.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
38.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
42.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-6.75$-7.25+6.9%
Q1 2026May 7, 2026$2.03$1.91+6.3%
Q4 2025Feb 10, 2026$1.86$1.81+2.8%
Q3 2025Oct 30, 2025$2.47$2.13+16.0%
Next earningsThu, Oct 29·consensus EPS $2.15

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.0B+4.4%79.2%37.2%$1.63$2.4B
Q4 FY25$7.9B+4.7%79.5%37.7%$1.76$3.1B
Q3 FY25$7.8B+3.0%79.8%42.8%$2.46$4.0B
Q2 FY25$7.1B+1.8%78.8%34.9%$1.57$720.0M

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$30.4B$30.2B – $30.7B-$0.75-$1.02 – -$0.6319
FY27$32.4B$31.2B – $33.8B$9.65$9.03 – $11.1118
FY28$34.2B$32.6B – $38.0B$10.55$9.37 – $11.8921
FY29$36.7B$35.6B – $38.2B$11.91$11.45 – $12.5510
FY30$38.5B$37.4B – $40.1B$12.96$12.45 – $13.6510

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.78%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+9.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 26Anthony WeltersDirector18.0K sh$2.7MSellAug 20Jeffrey BluestoneDirector5.0K sh$725KSellAug 17Andrew D DickinsonCFO3.0K sh$415KSellAug 17Johanna MercierChief Comm & Corp Aff Officer28.0K sh$3.9MSellAug 3O'day Daniel PatrickCEO15.0K sh$2.0MSellJul 15Andrew D DickinsonCFO3.0K sh$390KSellJul 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$390KSellJul 1O'day Daniel PatrickCEO15.0K sh$1.9MSellJun 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$372KSellJun 15Andrew D DickinsonCFO3.0K sh$376K
1–10 of 19
+ 37 other (14 exempts · 12 awards · 11 inkinds) in window

See when $GILD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentAug 7SC 13D/A
AI summary

the Reporting Person on July 17, 2020, as amended by Amendmen amended its 13D filing disclosing a beneficial ownership position of a 5%+ stake in GILD (GILD) as of 2026-08-07. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

S-3ASRAuto-shelf registrationAug 6S-3ASR
AI summary

Gilead Sciences, Inc. filed a new automatic shelf registration (S-3ASR) on August 6, 2026, registering an unspecified amount of debt securities, common stock, preferred stock, depositary shares, warrants, subscription rights, stock purchase contracts, and stock purchase units for issuance on a delayed or continuous basis. As a large accelerated filer, the S-3ASR becomes effective upon filing. No offering size or specific transaction is disclosed; this is a routine shelf refresh establishing the legal framework for future capital markets activity. Actual dilution or debt issuance would occur only upon a separate prospectus supplement.

SC 13D/AActivist amendmentMay 27SC 13D/A
AI summary

With filed Amendment No. 4 to Schedule 13D disclosing updated beneficial ownership in GILD (GILD). The filing covers approximately 4,977,089 shares of GILD. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementMay 208-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Gilead Sciences, Inc. (GILD) filed an 8-K on May 14, 2026 disclosing a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), and an other-event disclosure (Item 8.01). Gilead is a Foster City, California-based biopharmaceutical company focused on HIV, hepatitis, and oncology listed on Nasdaq. Filed concurrently with Gilead's $3B debt offering (424B5), Items 1.01 and 2.03 likely reflect the indenture for that debt issuance; this is a significant capital market event for the large-cap biopharma company.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Gilead Sciences, Inc. (GILD) priced a $3 billion four-tranche senior notes offering on May 18, 2026, comprising: $500M 4.250% Notes due May 20, 2028; $1B 4.400% Notes due May 20, 2029; $1B 4.600% Notes due May 20, 2031; and $500M 4.900% Notes due May 20, 2034. Interest is payable semi-annually on May 20 and November 20 each year starting November 2026. This is a large investment-grade debt capital markets transaction for Gilead; proceeds are likely for general corporate purposes, which may include funding pipeline acquisitions or licensing deals given Gilead's active M&A history.

424B5Prospectus supplement (offering)May 14424B5
AI summary

Gilead Sciences, Inc. (GILD) filed a preliminary 424B5 on May 14, 2026 for a multi-tranche senior notes offering with all pricing terms blank (amounts, rates, and maturities pending final terms). This preliminary filing precedes the final 424B5 pricing on May 18, 2026 which established the $3B four-tranche deal. The blank terms confirm this is the preliminary prospectus supplement and the actual deal economics were determined the following day.

8-KShareholder voteMay 48-K — Item 5.07: Shareholder vote
AI summary

Gilead Sciences Inc. (GILD) filed an 8-K reporting results of its annual shareholders' meeting under Item 5.07. Shareholders voted on standard governance matters including election of directors, ratification of the independent auditor, and advisory votes on executive compensation. All management-supported proposals passed as expected at the major pharmaceutical company. Detailed vote tallies by proposal are included in the filing.

SC 13D/AActivist amendmentApr 28SC 13D/A
AI summary

Gilead Sciences Inc. (GILD) received an amended Schedule 13D/A (Amendment No. 1) in connection with its ownership of Arcellx Inc. shares, where Gilead holds more than 5% and files as an active rather than passive holder. This amendment updates Gilead's beneficial ownership position in the oncology biotech following prior transactions. As a strategic investor with collaboration arrangements, Gilead filed under the more active 13D rather than passive 13G form. The filing discloses current share counts and updated purpose of the investment.

+ 18 other (3 SC TO-T/As · 2 10-Qs · 2 earnings 8-Ks · 2 13Fs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILDdefenseworld.net·3d agoBNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILDdefenseworld.net·3d agoBeacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILDdefenseworld.net·3d agoGilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infectionzacks.com·4d agoBamco Inc. NY Sells 12,000 Shares of Gilead Sciences, Inc. $GILDdefenseworld.net·4d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$NVO$JNJ$ABBV$AMGN$AZN
Voices on X · top 7 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport